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ABSTRACT 
Objective: Methylphenidate (MPH) is a derivative of piperidine, structurally related to amphetamine. It is the most widely psychostimulant used in 
Brazil for treating attention deficit disorder and hyperactivity. This drug was investigated in an epilepsy model induced by pilocarpine and on 
acetylcholinesterase (AChE) activity in young and adult mice.  
Methods: The control group was treated with saline. The treated groups received MPH (2.5, 5, 10 or 20 mg/kg) in single dose, followed by 
pilocarpine (400mg/Kg). The groups were observed for1h after treatment.  
Results: MPH, in all doses, was efficacious in decreasing both the latency to first seizures and the survival percentage in young and adult animals. 
Determination of AChE activity in the hippocampus and striatum of young and adult animals, after pilocarpine-induced status epilepticus, 
demonstrated that pretreatment with MPH reduced AChE activity only in the striatum.  
Conclusion: Our findings suggest that MPH has proconvulsant action and cholinergic neurotransmission system can play a role in this effect. 
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INTRODUCTION 
Attention-deficit/hyperactivity disorder (ADHD) is the most 
commonly diagnosed neuropsychiatric disorder in childhood, 
characterized by excessive levels of inattentiveness, impulsivity, and 
hyperactivity. The prevalence is variable but has been estimated at 
3-9% of school-aged children and 4% of adults [1, 2, 3]. Most ADHD 
patients benefit from treatment with methylphenidate 
hydrochloride (MPH), irrespective of the etiology of the disorder, 
effectively reducing symptoms in up to 70% of children [4]. 
However, recognition that ADHD persists into adulthood has led to 
increased use of MPH in adult patients [5]. 
Patients with ADHD exhibit dysfunction of dopaminergic and 
noradrenergic circuits in the brain, including the prefrontal and 
subcortical regions (e.g., striatum), and limbic regions (e.g., 
hippocampus) [6, 7, 8, 9]. 
Biochemical studies have shown that MPH, like amphetamine, 
enhances the release and blocks the reuptake of noradrenaline and 
dopamine in mammalian brain [10, 11, 12]. After administration, the 
distribution of MPH in brain is heterogeneous, and the maximum 
concentration occurs in the striatum, cortex, and cerebellum [12]. 
The acute administration of high doses of pilocarpine, a muscarinic 
cholinergic agonist, induces behavioural changes and seizures which 
progress after 1–2 h to long-lasting status epilepticus (SE) [13]. The 
neurochemical and behavioural characteristics of pilocarpine 
induced epilepsy in rodent models appear to be similar to those 
observed in human temporal lobe epilepsy [14]. Other studies 
suggest permanent changes in other neurochemical systems t such 
as the cholinergic system might be altered after seizures and SE 
induced by pilocarpine [15,16]. Therefore, we considered it 
important to study the enzymatic activity of acetylcholinesterase 
related to cholinergic system during seizures.  
Acetylcholinesterase (AChE) hydrolyzes the neurotransmitter 
acetylcholine (ACh) at the synaptic cleft of cholinergic synapses and 
neuromuscular junctions [17]. ACh has also been demonstrated to 
up- and down-regulate the development and differentiation of 
neural cells [18]. Increased ACh levels can dramatically alter 
neuronal function and excessive release and increased synthesis of 
this neurotransmitter has been related to SE [19]. In particular, it 
has been suggested that ACh, acting via intracellular messengers, 
may be involved in adult neuronal plasticity [20] and that an excess 
of ACh can induce SE in young and adult rats [15]. 
The aim of the present study was to investigate the effect of acute 
administration of MPH on cholinergic model of seizures induced by 
pilocarpine, as well as to determine the AChE activity in 
hippocampus and striatum of young and adult mice treated with 
MPH after pilocarpine-induced SE. 
MATERIAL AND METHODS 
Swiss, male mice young (8-15 g; 21 days old) and adult (25-30 g; 2 
months old) were obtained from Central Animal House of the 
Federal University of Ceara (UFC), Ceara, Brazil. Animals were 
housed in cages with free access to food and water. All animals were 
kept with standard light–dark cycle (lights on at 07:00 h a.m.). 
Experiments were performed under the consent and surveillance of 
Ethics Committee on Animal Research of UFC (CEPA; protocol 
number: 09/2012). 
Methylphenidate-Ritalin® was obtained commercially (Novartis 
Laboratorie). MPH was dissolved in distilled water. Pilocarpine 
hydrochloride (400 mg/kg (P400); (Sigma, Chemical USA) was 
administered in a volume of 10mL/kg injected intraperitoneally 
(i.p.). 
The animals were divided into six groups of 10 mice (n=10) and 
treated with MPH administered at doses of 2,5mg/kg (MPH 2,5); 5 
mg/kg (MPH 5); 10 mg/kg (MPH 10) and 20 mg/kg (MPH 20), 
intragastrically and, after 60 min, with (cholinergic agonist), 400 
mg/kg (P400), injected intraperitoneally (i.p.). One group received 
only P400. Each animal was placed in the acrylic observation 
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chamber (107mm×202mm×150 mm) immediately after injection of 
P400, and the occurrence of clonic convulsions and mortality, as well 
behavioural changes were observed for 1h.  After the SE, the animals 
that survived to P400 treatment (groups pretreated with MPH) and 
/ or a control group of 0.9% saline (group only used to measure the 
enzyme AChE) were sacrificed by decapitation 1 h after treatment 
and their brains were dissected on an ice cold plate to remove 
cerebral areas (striatum and hippocampus), then weighed and 
stored at -70 ◦ C. Tissues w ere ultrasonically hom ogenized in 1 m l 
of 0.05 M phosphate buffer, pH 7.0 to measure the activity of AChE. 
AChE activity was measured by the method of Ellman et al. [21] 
using 1mM acetylthiocholine, 1mM 5,5- dithiobis-(2-nitrobenzoic 
acid) and an incubation period of 10 min at 37 °C. The results were 
expressed as nmol acetylthiocholine hydrolyzed/min/mg protein. 
Results of latency to first seizure and neurochemical alterations 
were compared by one-way analysis of variance (ANOVA) followed 
by t Student–Newman–Keuls as post hoc test (P < 0.05) (Graphpad 
program Intuitive, Software for Science, San Diego, CA, USA). The 
number of animals that had seizures and the number that survived 
were expressed as percentages (latency of convulsion and survival 
percentage). 
RESULTS AND DISCUSSION 
A few minutes after the administration of P400, the animals showed 
peripheral cholinergic signs (100%) (miosis, piloerection, tear of 
blood, salivation, diarrhea, dieresis, tremors) and stereotyped 
movements (increased activity of biting, scratching, chewing and 
wet dog shakes - shaking like a wet dog), followed by limbic motor 
seizures. These changes were more pronounced in the pre-treated 
with MPH. Observing all animals, we found that the latency of 
convulsions was significantly decreased in the groups pretreated 
with MPH (MPH2,5+P400; MPH5+P400; MPH10+P400; 
MPH20+P400) when compared with the P400 group in young mice 
[P400 = 538,7±39,63 (n=13); MPH2,5+P400 = 493,7±34,56 (n=13); 
MPH5+P400 = 423,8±25,63 (n=13); MPH10+P400 = 378,2±22,41 
(n=15); MPH20+P400 = 357,2±25,28 (n=15)] (Figure 1A). 
 
There was also a decrease in adult mice in the latency of seizures in 
animals pretreated with MPH when compared to the P400 [P400 = 
875,7±42,80 (n=13); MPH2,5+P400 = 564,3±44,76 (n=13); 
MPH5+P400 = 632,3±46,90 (n=13); MPH10+P400 = 677,9±43,54 
(n=15); MPH20+P400 = 696,0±25,99 (n=15)] (Figure 1B).  
 
Fig. 1: It shows the latency of seizures (in seconds) in animal 
groups pretreated with Methylphenidate (MPH: 2,5; 5; 10 and 
20 mg/kg) and after with Pilocarpine (P400mg/kg). 
Where, A. Young animals and B. Adult animals. Data represent mean 
± SEM. *P<0,05; **P<0,01 and ***P<0,001 compared to P400 alone 
(control group) (ANOVA and Student- Newman- Keuls). 
In young animals there was a decrease in the percentage of survival 
in the group pretreated with MPH at all doses, where 100 % 
[MPH2,5+P400 (n=13); MPH5+P400 (n=13); MPH10+P400 (n=15); 
MPH20+P400 (n=15)] of animals died when compared to the P400 
group (76,9%;10/13 of the animals died) over the time period of the 
experiment (Figure 2A). 
In adult animals, it occurred a decreased in the percentage of 
survival at all doses, where 100% of the animals died 
[(MPH2,5+P400 (n=8); MPH5+P400 (n=8); MPH10+P400 (n=14); 
MPH20+P400 (n=12)] compared to P400 group, where 64,28% 
(9/14) of the animal died over the time period of the experiment 
(Figure 2B).  
 
  
Fig. 2:  It hows the effect of methylphenidate on percentage of 
survival of animal groups pretreated with Methylphenidate 
(MPH: 2,5; 5; 10 and 20 mg/kg) and after with Pilocarpine 
(P400mg/kg). 
 
Where, A. Young animals and B. Adult animals 
The investigation of the enzymatic activity of AChE was performed 
in hippocampus and striatum of young and adult mice, pertaining to 
the following treatment groups: CTRL (saline 0,9%); 
methylphenidate (MPH2,5+P400; MPH5+P400; MPH10+P400; 
MPH20+P400); pilocarpine, 400mg/Kg (P400). The results were 
expressed as nmol/mg protein/ minute.  
In young animals: The administration only of P400 was able to 
significantly reduce the AChE activity in the hippocampus and 
striatum as compared to CTRL. No significant change was observed 
in the hippocampus of animals belonging to different groups of MPH 
pretreatment followed by P400 compared to CTRL and P400 [CTRL 
= 49,41±3,64 (n=6); P400 = 25,55+2,31 (n=8); MPH2,5+P400 = 
42,19±7,36 (n=6); MPH5+P400 = 42,25±5,11 (n=6); MPH10+P400 = 
53,28±4,50 (n=6); MPH20+P400 = 33,16±3,86 (n=6)] (Figure 3A). 
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However, pretreatment with MPH followed by administration of 
P400 (MPH5+P400; MPH10+P400; MPH20+P400) reduced 
significantly the level of AChE enzyme activity in the striatum 
compared to CTRL [CTRL = 83,54±5,14 (n=7); P400 = 42,75±9,00 
(n=6); MPH2,5+P400 = 67,10±5,37 (n=8); MPH5±P400 = 57,40±6,43 
(n=7); MPH10±P400 = 43,03±7,60 (n=7); MPH20±P400 = 
59,38±5,54 (n=6)] (Figure 4A).  
In adult animals: The administration of P400 was able to reduce 
significantly AChE activity in the hippocampus and striatum 
compared to CTRL. No significant change was observed in the 
hippocampus of animals belonging to different groups of MPH 
pretreatment followed by P400 compared to CTRL and P400 [CTRL 
= 63,06±7,10 (n=9); P400 = 19,04±2,80 (n=8); MPH2,5+P400 = 
45,40±4,02 (n=9); MPH5+P400 = 40,61±5,99 (n=8); MPH10+P400 = 
69,84±5,23 (n=8); MPH20+P400 = 54,72±7,76 (n=7)] (Figure 3B). 
In the striatum, the groups pretreated with MPH followed by 
administration of P400 (MPH2,5+P400 and MPH5+P400) reduced 
significantly the level of AChE enzyme activity when compared to 
CTRL [CTRL = 141,8±12,71 (n=8); P400 = 48,76±4,70 (n=8); 
MPH2,5+P400 = 64,48±4,34 (n=9); MPH5+P400 = 56,50±5,30 
(n=10); MPH10+P400 = 136,7±17,70 (n=6); MPH20+P400 = 












































Fig. 3: It shows the effects of methylphenidate on the activity of 
acetylcholinesterase (AChE) in the hippocampus during 
seizures induced by Pilocarpine 400 mg/kg (P400). 
 
Where, A. Young animals and B. Adult animals. Data represent 
mean± SEM. **P<0,01 and ***P<0,001 compared to control group 
(ANOVA and Student-Keuls). 
 
Studies have shown high rates of neuropsychiatric comorbidities 
associated with ADHD [22, 23, 24]. A consensus of international 
experts emphasized the message that "comorbidity is the norm 
rather than exception" [23]. Souza et al [24] studied a group of 
children and adolescents, and found that more than 85% had 
comorbid disorders. Conduct disorders and oppositional defiance 
were the most common.. Other studies also indicate the presence of 
anxiety disorders, depression, bipolar disorder and motor tics [25]. 
ADHD symptoms can often precede the first recognized seizures or 
can become more apparent during the course of the epilepsy as the 

















































Fig. 4: It shows the effects of methylphenidate on the activity of 
acetylcholinesterase (AChE) in the hippocampus during 
seizures induced by Pilocarpine 400 mg/kg (P400) 
 
Where, A. Young animals and B. Adult animals. Data represent 
mean± SEM. *P<0,05; **P<0,01 and ***P<0,001 compared to control 
group (ANOVA and Student-Keuls). 
There is a warning in the FDA-approved package insert for all MPH 
products advising against use of MPH in patients with a history of 
seizures. However, the information to support this warning is very 
limited and contradicted by other lines of evidence [27]. 
MPH has been tested in a model of seizures induced by sensitization 
with low-intensity brain stimulation (kindling). In this model, MPH 
prolonged the duration of kindled seizures, but only weakly [28]. 
Overdosing on MPH may lead to stimulation of the central nervous 
system or sympathomimetic system, causing severe manifestations, 
including seizures [29]. The results of this study show that the 
seizures in the animals pretreated with MPH were potentiated, 
shown by reduced latency periods to onset of first seizure and time 
to death following administration of P400. This effect was observed 
in both young and adult animals.  
The investigation of the putative mechanism involving the 
cholinergic system, was performed using pilocarpine, a muscarinic 
agonist, which in high doses induces behavioral changes, such as 
seizures and brain damage in rodents via cortical overstimulation 
[30,14]. The reduction of the latency period with MPH pro-treatment 
for seizures and survival suggest that MPH is involved in cholinergic 
pathways and does not protect against seizures in cholinergic 
models. 
To further elucidate the role of cholinergic transmission in 
convulsions and death observed with MPH, the brain AChE activity 
of the animals was determined. Pilocarpine exacerbates cholinergic 
activity, probably due to direct influence, increasing the ACh current, 
modifying the binding of muscarinic receptors [31] and decreasing 
the activity AChE [32]. AChE is considered essential for normal 
functioning of the nervous system, as it limits the action of 
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acetylcholine, as soon as it is released in the synaptic clefts. It is 
speculated that the enzyme activity could affect the susceptibility to 
seizures induced by pilocarpine [33]. 
The inhibition of AChE activity induced by P400, in seizure models, 
has been previously reported [14, 34]. In the present study, 
consistent with the current literature, P400 induced a reduction in 
activity of this enzyme. Pre-treatment with MPH in young and adults 
animals reduced the enzyme activity in the striatum when compared 
to the control group. There were no significant differences in the 
hippocampus of young and adult animals pretreated with MPH. It 
has been previously described that treatment with MPH only 
increases the activity of AChE in the striatum but not in the 
hippocampus of rats [35]. 
Cholinergic activation is essential for the initiation of the seizures 
models in temporal lobe epilepsy, since these fits can be blocked by 
pretreatment with the antagonist atropine [36]. It is believed that 
the decrease of acetylcholine metabolism by reducing or blocking 
the activity of AChE, can facilitate installation of seizure activity, by 
virtue of increasing concentration of endougenous acetylcholine, 
which can directly activate the cholinergic system and, directly or 
indirectly, induce neurochemical changes in other neurotransmitter 
systems, including, glutamatergic and GABAergic, since these may be 
implicated in the establishment and development of limbic seizures 
[31]. Our data suggest that the mechanism of seizures caused by 
MPH may involve a modulation in the cholinergic system, with 
possible reduction of the activity of acetylcholinesterase, resulting in 
increased levels of acetylcholine [37]. 
CONCLUSION 
In summary, this study suggests a modulating effect, exerted by 
MPH, on the functioning of the muscarinic cholinergic system, in the 
central level, as an alternative mechanism for potentiation of 
seizures in the P400 model, suggesting a possible cholinergic 
mechanism involved, since the drug reduced the activity of 
acetylcholinesterase. 
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